Muscle News and Research

RSS

Senators return to full plate, featuring health bills

"The focus on health care as Congress reconvenes Tuesday after its monthlong recess is nearly all-consuming," The Associated Press reports. "At stake, beyond the future of health care, is an accomplishment Democrats need to convince voters they deserve to remain in power." Financial legislation, consumer protections and clean energy are also still on the table in the Senate (Abrams, 9/8).

9 Sep 2009

Small molecule blocks aberrant pathway associated with myotonic dystrophy

Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.

8 Sep 2009

Muscular Dystrophy Canada to host the 44th Jerry Lewis Labour Day Telethon

Muscular Dystrophy Canada is hosting the 44th Annual Jerry Lewis Labour Day Telethon to support those living with a neuromuscular disorder.

7 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Scientists identify new genetic variations that are associated with type 2 diabetes

Scientists have identified a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin, in a new study published today in Nature Genetics.

7 Sep 2009

Olympic gold medalist Shannon Miller to campaign for Stemcyte

StemCyte, Inc., one of the world's preeminent cord blood banks, today announced that Shannon Miller, a 7-time Olympic Medalist and 9-time World Medalist, has signed an endorsement partnership agreement and will appear in a series of advertising and public awareness campaigns for the company.

5 Sep 2009

Study reveals elevated cTnT levels in post-CABG patients

Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, are powerfully prognostic, a team of researchers from the Massachusetts General Hospital (MGH) Heart Center has found.

5 Sep 2009

No performance enhancing effect of quercetin seen, according to a study

The antioxidant quercetin is increasingly being marketed as a supplement that boosts athletic performance, but a new University of Georgia study finds that it is no better than a placebo.

4 Sep 2009

Americans' health perceptions contradict national statistics

We think we’re healthier than we actually are, suggests a new survey from market research leader Mintel. Surveying Americans about their health, Mintel found people’s perceptions strongly contradict national statistics about obesity, illness and wellness.

4 Sep 2009

Gene-Eden antiviral supplement may offer protection against swine flu

Everyone is looking for ways to protect themselves against the swine flu virus. Let me tell you about my personal encounter with the virus. About three months ago, I read an article on Dr. Hanan Polansky's book, where he describes his discovery of the relationship between chronic viruses and chronic disease. After I read the article, I started taking Gene-Eden, a broad range antiviral supplement, to reduce the number of chronic viruses in my body.

3 Sep 2009

First world conference on AMIS procedure

Medacta International, a manufacturer of total joint replacement systems and innovative surgical techniques, today announced that it is hosting the first world conference on the anterior hip approach, also referred to as the AMIS procedure.

3 Sep 2009

m.pulse system for MCP therapy installed in ten hospitals

Cardiola AG announced today that it has placed its patented m.pulse system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse is the world’s first and only device enabling CAD patients to receive MCP therapy at home.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

Ferguson, the founding professional agency of CommonHealth, today announced the launch of the Ferguson OTC (over-the-counter) Center of Excellence, a new initiative designed to address the rapid increase of promotion and use of OTC drugs.

2 Sep 2009

Neuromuscular disorders common among Canadians

September is Muscular Dystrophy Awareness Month. There are more than 100 neuromuscular disorders and it is estimated more than 50,000 Canadians are affected by one form or another. Each form is caused by an error in a specific gene related to muscle function.

2 Sep 2009

Genes that regulate the energy consumption of cells have a different structure and expression in diabetics

Genes that regulate the energy consumption of cells have a different structure and expression in type II diabetics than they do in healthy people, according to a new study from the Swedish medical university Karolinska Institutet published in Cell Metabolism.

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

Ground breaking surgery leaves no unsightly scar

Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.

2 Sep 2009